Source: VentriPoint Diagnostics Ltd.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Ventripoint (VPT) will be exhibiting at the 70th European Society of Cardiology (ESC) Congress in Barcelona, Spain, from August 26 to 29
  • According to the Congress website reports, 40,000 participants from 170 countries will hear 5,000 medical presentations during the congress
  • This is another opportunity for Ventripoint to inform the cardiology community about its innovative VMS+ products
  • Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography
  • VentriPoint Diagnostics Ltd. (VPT) is down 1.59 per cent, trading at C$0.31 per share at 2:16 pm ET

Ventripoint (VPT) will be exhibiting at the 70th European Society of Cardiology (ESC) Congress in Barcelona, Spain, from August 26 to 29.

The spotlight in 2022 is “Cardiac imaging,” ever more critical in cardiovascular medicine with its profound implications from prevention to diagnosis, clinical decision-making, guiding interventions and therapeutic procedures.

According to the congress website, 40,000 participants from 170 countries will hear 5,000 medical presentations. The ESC will hold the conference virtually and in person for the first time. It will provide access to the latest cardiology research and clinical updates from anywhere in the world.

The ESC comprises clinicians, scientists, and other professionals in the cardiology field. The ESC aims to unite national cardiac societies worldwide to study further and understand cardiovascular disease.

This is another opportunity for Ventripoint to inform the cardiology community about its innovative VMS+ products. This follows the successful AEPC conference this past May in Geneva and the ASE conference in June in Seattle.

Ventripoint has become an industry leader in applying AI (Artificial Intelligence) to echocardiography. Ventripoint’s VMS+ products are powered by its proprietary KBR technology, resulting from a decade of development. It provides accurate volumetric cardiac measurements equivalent to MRI.

VentriPoint Diagnostics Ltd. (VPT) is down 1.59 per cent, trading at C$0.31 per share at 2:16 pm ET.


More From The Market Herald
The Market Herald Video

" BioVaxys (CSE:BIOV) expands vaccines intellectual property portfolio

BioVaxys Technology Corp. (BIOV) has broadened patent coverage for its viral vaccine platform.

" Lumiera Health (TSXV:NHP) partners with natural health industry leader

Lumiera Health (NHP) has signed an MoU to explore a strategic partnership with one of Quebec’s leaders in the natural health industry.

" No pain, no blood: BETTER Type 2 diabetes testing is coming to market

Over the past two years, reporting on the Covid-19 pandemic has dominated media airwaves.

" Reunion (TSX:REUN) appoints Greg Mayes as President and CEO

Reunion Neuroscience (REUN) (formerly Field Trip Health Ltd.) has appointed Greg Mayes as President and Chief Executive Officer.